Abstract
A sensitive and specific liquid chromatography–tandem mass spectrometry method was developed and validated for the quantification of the plant natural product silvestrol in mice, using ansamitocin P-3 as the internal standard. The method was validated in plasma with a lower limit of quantification of 1 ng/mL, accuracy ranging from 87 to 114%, and precision (coefficient of variation) below 15%. The validated method was used to characterize pharmacokinetics in C57BL/6 mice and metabolism in mouse, human and rat plasma, and liver microsomes. Mice were dosed with silvestrol formulated in hydroxypropyl-β-cyclodextrin via intravenous, intraperitoneal, and oral routes followed by blood sampling up to 24 h. Intraperitoneal systemic availability was 100%, but oral administration resulted in only 1.7% bioavailability. Gradual degradation of silvestrol was observed in mouse and human plasma, with approximately 60% of the parent drug remaining after 6 h. In rat plasma, however, silvestrol was completely converted to silvestric acid (SA) within 10 min. Evaluation in microsomes provided further evidence that the main metabolite formed was SA, which subsequently showed no cytotoxic or cytostatic activity in a silvestrol-sensitive lymphoblastic cell line. The ability of the analytical assay to measure tissue levels of silvestrol was evaluated in liver, brain, kidney, and spleen. Results indicated the method was capable of accurately measuring tissue levels of silvestrol and suggested it has a relatively low distribution to brain. Together, these data suggest an overall favorable pharmacokinetic profile of silvestrol in mice and provide crucial information for its continued development toward potential clinical testing.
Similar content being viewed by others
References
Hwang BY et al. Silvestrol and episilvestrol, potential anticancer rocaglate derivatives from Aglaia silvestris. J Org Chem. 2004;69(10):3350–8. ibid. p. 6156.
King ML. X-Ray crystal-structure of rocaglamide, a novel antileukemic 1H-cyclopenta[b]benzofuran from Aglaia elliptifolia. J Chem Soc Chem Commun. 1982;20:1150–1.
Trost BM et al. An unusual oxidative cyclization—A synthesis and absolute stereochemical assignment of (−)-rocaglamide. J Am Chem Soc. 1990;112(24):9022–4.
Proksch P et al. Chemistry and biological activity of rocaglamide derivatives and related compounds in Aglaia species (Meliaceae). Curr Org Chem. 2001;5(9):923–38.
Kim S et al. Potential of cyclopenta[b]benzofurans from Aglaia species in cancer chemotherapy. Anticancer Agents Med Chem. 2006;6(4):319–45.
Gerard B et al. Enantioselective synthesis of the complex rocaglate (−)-silvestrol. Angew Chem Int Ed Engl. 2007;46(41):7831–4.
El Sous M et al. Total synthesis of (−)-episilvestrol and (−)-silvestrol. Angew Chem Int Ed Engl. 2007;46(41):7835–8.
Adams TE et al. Total synthesis of the potent anticancer Aglaia metabolites (−)-silvestrol and (−)-episilvestrol and the active analogue (−)-4′-desmethoxyepisilvestrol. J Am Chem Soc. 2009;131(4):1607–16.
Meurer-Grimes, B.M., et al., Therapeutic compounds and methods U.S. Pat.,US 6710075 B2. 2004.
Mi Q et al. Silvestrol regulates G2/M checkpoint genes independent of p53 activity. Anticancer Res. 2006;26(5A):3349–56.
Kim S et al. Silvestrol, a potential anticancer rocaglate derivative from Aglaia foveolata, induces apoptosis in LNCaP cells through the mitochondrial/apoptosome pathway without activation of executioner caspase-3 or -7. Anticancer Res. 2007;27(4B):2175–83.
Lucas DM et al. The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo. Blood. 2009;113(19):4656–66.
Bordeleau ME et al. Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model. J Clin Invest. 2008;118(7):2651–60.
Cencic R et al. Antitumor activity and mechanism of action of the cyclopenta[b]benzofuran, silvestrol. PLoS ONE. 2009;4(4):e5223.
Ramaswamy, B., et al. A dose-finding, pharmacokinetic and pharmacodynamic study of a novel schedule of flavopiridol in patients with advanced solid tumors. Invest New Drugs. 2010. Oct 12. doi:10.1007/s10637-010-9563-7.
George TG et al. Antikinetoplastid antimitotic activity and metabolic stability of dinitroaniline sulfonamides and benzamides. Bioorg Med Chem. 2006;14(16):5699–710.
Acknowledgements
This work was supported by the U.S. National Cancer Institute [Contract N01-CM-52205 to KKC, P01-CA125066 to ADK, SPORE P50-CA140158 to MRG, and The Ohio State University Comprehensive Cancer Center Core Grant (P30-CA016058-35) supporting the Experimental Therapeutics Program and Pharmacoanalytical Shared Resource].
Author information
Authors and Affiliations
Corresponding authors
Additional information
U.V.R. Vijaya Saradhi and Sneha V. Gupta contributed equally to this work.
Rights and permissions
About this article
Cite this article
Saradhi, U.V.R.V., Gupta, S.V., Chiu, M. et al. Characterization of Silvestrol Pharmacokinetics in Mice Using Liquid Chromatography–Tandem Mass Spectrometry. AAPS J 13, 347–356 (2011). https://doi.org/10.1208/s12248-011-9273-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1208/s12248-011-9273-x